NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 980.3 DKK | +1.34% |
|
+0.65% | +40.42% |
| Jul. 12 | Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market | RE |
| Jul. 12 | Ozempic linked with lower dementia risk, nicotine use, British study finds | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
980.3
DKK
Average target price
956.5
DKK
Spread / Average Target
-2.43%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +40.42% | 636B | |
| +62.66% | 854B | |
| -4.37% | 361B | |
| +17.16% | 324B | |
| +9.87% | 301B | |
| +15.66% | 247B | |
| +4.21% | 230B | |
| +17.90% | 228B | |
| +14.86% | 177B | |
| +0.45% | 164B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Novo Nordisk to Limit Launch of Wegovy in China, Executive Says
